Genetic testing in heritable cardiac arrhythmia syndromes: Differentiating pathogenic mutations from background genetic noise

Current Opinion in Cardiology

Volumn 28, Issue 1, 2013, Pages 63-71

  Giudicessi, John R ^a   Ackerman, Michael J ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b Windland Smith Rice Sudden Death Genomics Laboratory   (United States)

Author keywords

Brugada syndrome; genetics; ion channels; long QT syndrome; sudden death

Indexed keywords

BRUGADA SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; HEART ARRHYTHMIA; HERITABLE CARDIAC ARRHYTHMIA SYNDROME; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; REVIEW; SIGNAL NOISE RATIO;

BRUGADA SYNDROME; DEATH, SUDDEN, CARDIAC; DIAGNOSIS, DIFFERENTIAL; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEART RATE; HUMANS; INHERITANCE PATTERNS; ION CHANNELS; LONG QT SYNDROME; MUTATION; PROGNOSIS; SYNDROME;

EID: 84871630327     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835b0a41     Document Type: Review

References (71)

1. Ruan Y, Liu N, Priori SG. Sodium channel mutations and arrhythmias. Nat Rev Cardiol 2009; 6:337-348.
2. Cerrone M, Priori SG. Genetics of sudden death: focus on inherited channelopathies. Eur Heart J 2011; 32:2109-2118.
3. Giudicessi JR, Ackerman MJ. Potassium-channel mutations and cardiac arrhythmias: diagnosis and therapy. Nat Rev Cardiol 2012; 9:319-332.
4. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee toDevelop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247-e346.
5. Heart Rhythm UK Familial Sudden Death Syndromes Statement Development Group. Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement. Heart 2008; 94:502-507.
6. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart RhythmSociety joint position paper. Can J Cardiol 2011; 27:232-245.
7. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308-1339.
8. Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. BMJ 2001; 322:1052-1056. (Pubitemid 32396424)
9. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle: will we get our wish? N Engl J Med 2008; 358:105-107.
10. Cotton RG, Scriver CR. Proof of 'disease causing' mutation. Hum Mutat 1998; 12:1-3. (Pubitemid 28262218)
11. Ingles J, Zodgekar PR, Yeates L, et al. Guidelines for genetic testing of inherited cardiac disorders. Heart Lung Circ 2011; 20:681-687.
12. Giudicessi JR, Kapplinger JD, Tester DJ, et al. Phylogenetic and physicochemical analyses enhance the classification of rare non-synonymous single nucleotide variants in type 1 and 2 Long QT syndrome. Circ Cardiovasc Genet 2012; 5:519-528.
13. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009; 120:1761-1767.
14. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet 2008; 372:750-763.
15. Priori SG, NapolitanoC, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99:529-533. (Pubitemid 29061868)
16. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327:846-852.
17. Amin AS, Giudicessi JR, Tijsen AJ, et al. Variants in the 3' untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J 2012; 33:714-723.
18. Tester DJ, Will ML, Haglund CM, AckermanMJ. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 2006; 47:764-768. (Pubitemid 43243098)
19. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17-23. (Pubitemid 26011314)
20. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80:795-803.
21. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80:805-811.
22. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421:634-639. (Pubitemid 36227671)
23. Duggal P, Vesely MR, Wattanasirichaigoon D, et al. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome. Circulation 1998; 97:142-146. (Pubitemid 28124670)
24. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178-1185.
25. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105:511-519. (Pubitemid 32520856)
26. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119:19-31. (Pubitemid 39349317)
27. Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006; 114:2104-2112. (Pubitemid 44747890)
28. Medeiros-DomingoA, Kaku T, Tester DJ, et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 2007; 116:134-142. (Pubitemid 47057518)
29. Chen L, Marquardt ML, Tester DJ, et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci U S A 2007; 104:20990-20995.
30. Ueda K, Valdivia C, Medeiros-DomingoA, et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A 2008; 105:9355-9360.
31. Yang Y, Liang B, Liu J, et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010; 86:872-880.
32. Priori SG, NapolitanoC, TisoN, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103:196-200. (Pubitemid 32095402)
33. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamineinduced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69:1378-1384. (Pubitemid 33124218)
34. Tester DJ, Arya P, Will M, et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 2006; 3:800-805. (Pubitemid 43960545)
35. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:293-296. (Pubitemid 28155103)
36. London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na current and causes inherited arrhythmias. Circulation 2007; 116:2260-2268. (Pubitemid 350100331)
37. Antzelevitch C, Pollevick GD, CordeiroJM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by STsegment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442-449. (Pubitemid 46184195)
38. CordeiroJM, Marieb M, Pfeiffer R, et al. Accelerated inactivation of the L-type calcium current due toa mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol 2009; 46:695-703.
39. Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118:2260-2268. (Pubitemid 351872343)
40. Delpon E, CordeiroJM, Nunez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008; 1:209-218.
41. Hu D, Barajas-Martinez H, Burashnikov E, et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009; 2:270-278.
42. Medeiros-DomingoA, Tan BH, Crotti L, et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 2010; 7:1466-1471.
43. Barajas-Martinez H, Hu D, Ferrer T, et al. Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm 2012; 9:548-555.
44. Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010; 7:1872-1882.
45. Giudicessi JR, Ye D, Tester DJ, et al. Transient outward current (I(to)) gain-offunction mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 2011; 8:1024-1032.
46. Giudicessi JR, Ye D, Kritzberger CJ, et al. Novel mutations in the KCND3-encoded Kv4.3 K channel associated with autopsy-negative sudden unexplained death. Hum Mutat 2012; 33:989-997.
47. Kattygnarath D, Maugenre S, Neyroud N, et al. MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet 2011; 4:261-268.
48. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005; 2:507-517. (Pubitemid 40521365)
49. Eddy CA, MacCormick JM, Chung SK, et al. Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome. Heart Rhythm 2008; 5:1275-1281.
50. Tester DJ, Benton AJ, Train L, et al. Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Am J Cardiol 2010; 106:1124-1128.
51. Kapa S, Tester DJ, Salisbury BA, et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation 2009; 120:1752-1760.
52. Priori SG, Schwartz PJ, NapolitanoC, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348:1866-1874. (Pubitemid 36532312)
53. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of betablocker therapy in congenital long-QT syndrome. Circulation 2000; 101: 616-623. (Pubitemid 30094732)
54. Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 2005; 10 (4 Suppl):59-66. (Pubitemid 44933555)
55. Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response tomexiletine in long-QT syndrome type 3 patients. Circulation 2007; 116:1137-1144. (Pubitemid 47360216)
56. Priori SG, NapolitanoC, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69-74. (Pubitemid 34747444)
57. Medeiros-DomingoA, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009; 54:2065-2074.
58. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation 2011; 123:1021-1037.
59. Krahn AD, Gollob M, Yee R, et al. Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion. Circulation 2005; 112:2228-2234. (Pubitemid 41464564)
60. Postma AV, Denjoy I, Kamblock J, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005; 42:863-870. (Pubitemid 41598196)
61. van der Werf C, Nederend I, Hofman N, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012; 5:748-756.
62. Bai R, NapolitanoC, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how toprioritize access togenetic testing. Circ Arrhythm Electrophysiol 2009; 2:6-15.
63. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference-endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659-670.
64. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20:1391-1396.
65. Chen PS, Priori SG. The Brugada syndrome. J Am Coll Cardiol 2008; 51:1176-1180.
66. Shimizu W. Clinical impact of genetic studies in lethal inherited cardiac arrhythmias. Circ J 2008; 72:1926-1936.
67. Priori SG, NapolitanoC,Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 2000; 102:2509-2515.
68. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat 2003; 21:651-652.
69. Priori SG, NapolitanoC, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105:1342-1347. (Pubitemid 34260426)
70. Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1-through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol 2012; 60:1410-1418.
71. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010; 7:33-46.